Pfizer Inc (PFE)
Working capital turnover
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 58,497,000 | 68,538,000 | 77,944,000 | 92,952,000 | 100,331,000 | 100,771,000 | 101,921,000 | 92,738,000 | 81,285,000 | 63,407,000 | 51,332,000 | 44,201,000 | 41,650,000 | 47,096,000 | 47,667,000 | 49,131,000 | 50,098,000 | 51,534,000 | 52,176,000 | 52,443,000 |
| Total current assets | US$ in thousands | 43,333,000 | 74,012,000 | 73,347,000 | 50,078,000 | 51,259,000 | 70,403,000 | 67,466,000 | 54,420,000 | 59,693,000 | 57,900,000 | 48,814,000 | 39,533,000 | 35,067,000 | 47,739,000 | 46,424,000 | 34,738,000 | 32,803,000 | 33,459,000 | 47,073,000 | 45,290,000 |
| Total current liabilities | US$ in thousands | 47,794,000 | 31,136,000 | 34,647,000 | 36,562,000 | 42,138,000 | 44,314,000 | 47,410,000 | 39,268,000 | 42,671,000 | 41,803,000 | 35,664,000 | 26,652,000 | 25,920,000 | 34,154,000 | 32,723,000 | 33,890,000 | 37,304,000 | 36,974,000 | 32,030,000 | 29,423,000 |
| Working capital turnover | — | 1.60 | 2.01 | 6.88 | 11.00 | 3.86 | 5.08 | 6.12 | 4.78 | 3.94 | 3.90 | 3.43 | 4.55 | 3.47 | 3.48 | 57.94 | — | — | 3.47 | 3.31 |
December 31, 2023 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $58,497,000K ÷ ($43,333,000K – $47,794,000K)
= —
The working capital turnover ratio for Pfizer Inc. fluctuated over the past eight quarters, ranging from a low of 1.60 in Q3 2023 to a high of 11.00 in Q4 2022. This ratio measures how efficiently the company is utilizing its working capital to generate sales revenue.
In Q1 2023, the working capital turnover ratio surged to 6.88, indicating a significant improvement in the company's ability to convert its working capital into revenue. This may suggest a more streamlined operating cycle and effective management of current assets and liabilities during that period.
Overall, Pfizer's working capital turnover has shown variability, with some quarters exhibiting particularly strong performance, while others showing lower efficiency in utilizing working capital. Further analysis and comparison with industry benchmarks can provide additional insights into the company's working capital management practices.
Peer comparison
Dec 31, 2023